Search

Regeneron Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

655.96 0.92

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

653.85

Max

660.01

Galvenie mērījumi

By Trading Economics

Ienākumi

-117M

727M

Pārdošana

-279M

3.6B

P/E

Sektora vidējais

16.527

62.58

EPS

9.47

Dividenžu ienesīgums

0.53

Peļņas marža

20.17

Darbinieki

15,343

EBITDA

-234M

967M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+24.22% upside

Dividendes

By Acuity

Dividenžu ienesīgums

Sektora vidējais

0.53%

2.19%

Nākamie ieņēmumi

2026. g. 30. jūl.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-7.6B

70B

Iepriekšējā atvēršanas cena

655.04

Iepriekšējā slēgšanas cena

655.96

Ziņu noskaņojums

By Acuity

57%

43%

274 / 340 Rangs Healthcare

Regeneron Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 25. jūl. 00:02 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, reaching the upper end of their one-month trading range. No specific news was identified.

2026. g. 24. jūl. 20:13 UTC

Regeneron Pharmaceuticals Inc shares are higher in after-market trading, remaining near the upper end of their one-month range. No specific news was identified.

2026. g. 23. jūl. 09:56 UTC

Regeneron Pharmaceuticals Inc shares are modestly higher in pre-market trading. No specific company news was identified to explain the price movement.

2026. g. 22. jūl. 23:46 UTC

Regeneron Pharmaceuticals shares are higher in after-hours trading, peaking post-market despite cautious sentiment from rising crude oil prices and geopolitical tensions.

2026. g. 21. jūl. 23:51 UTC

News

Regeneron Pharmaceuticals faces a class action lawsuit for securities fraud over misleading claims about Fianlimab-Libtayo trial results. Shares are lower in after-hours trading.

2026. g. 17. jūl. 19:26 UTC

Social Media
News

Regeneron Pharmaceuticals faces a class action lawsuit from Levi & Korsinsky, LLP, contributing to ongoing declines in the stock amid market volatility.

2026. g. 16. jūl. 20:03 UTC

Regeneron Pharmaceuticals is trading higher, supported by gains in the Biotechnology sub-sector amid a strong broader market performance today.

2026. g. 15. jūl. 19:16 UTC

Regeneron Pharmaceuticals Inc shares are higher Wednesday, recovering from an earlier dip and remaining above the 20-day moving average. No specific news was identified.

2026. g. 13. jūl. 19:26 UTC

Regeneron Pharmaceuticals shares are lower today amid broader market declines driven by rising oil prices and geopolitical tensions. No specific company news was identified.

2026. g. 11. jūl. 00:01 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, reflecting a notable gain near the upper end of its one-month trading range.

2026. g. 10. jūl. 19:26 UTC

Correlated Moves

Regeneron Pharmaceuticals Inc shares declined amid broader biotechnology sector pressures and geopolitical tensions, despite earlier reaching a session high before pulling back.

2026. g. 9. jūl. 23:51 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours following a weak trading session, despite a report showing a decrease in initial jobless claims.

2026. g. 8. jūl. 19:53 UTC

News

Regeneron Pharmaceuticals shares are lower, pressured by declines in the Biotechnology sector and a reduced price target of $730 from Morgan Stanley.

2026. g. 7. jūl. 23:06 UTC

Regeneron Pharmaceuticals Inc shares are higher in after-market trading, supported by stable performance and positioning above the 20-day moving average.

2026. g. 6. jūl. 23:01 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours, with no specific news identified to explain the decline amid mixed market sentiment.

2026. g. 2. jūl. 23:26 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours, despite a lower-than-expected jobs report easing rate hike fears and boosting sentiment for some risk assets.

2026. g. 1. jūl. 19:16 UTC

Regeneron Pharmaceuticals is trading higher, reflecting positive biotechnology sector performance. The stock remains above its 20-day moving average and near a one-month peak.

2026. g. 30. jūn. 23:16 UTC

Regeneron Pharmaceuticals shares remain roughly flat in after-market trading, following three consecutive sessions of declines and no specific news identified.

2026. g. 29. jūn. 23:06 UTC

News

Regeneron Pharmaceuticals will join the FDA's PreCheck Pilot Program to enhance domestic drug manufacturing. Shares are trading lower in after-market hours.

2026. g. 26. jūn. 23:36 UTC

Regeneron Pharmaceuticals Inc shares are trading higher in after-market hours, moving within a notable range above their 20-day moving average.

2026. g. 25. jūn. 23:16 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours, retracing from an early peak following five consecutive daily gains. No specific news was identified.

2026. g. 24. jūn. 23:01 UTC

Regeneron Pharmaceuticals Inc shares are lower after-market hours, continuing a decline since Wednesday's close amid positive sentiment in the financial sector.

2026. g. 23. jūn. 23:06 UTC

Regeneron Pharmaceuticals Inc shares are trading lower in after-market hours. Broader market trends may be influencing the stock's movement amid European market declines.

2026. g. 22. jūn. 19:56 UTC

Social Media
News

Regeneron Pharmaceuticals' cemdisiran submissions accepted by the FDA and European Medicines Agency. Shares are gaining amid positive regulatory developments.

2026. g. 18. jūn. 23:51 UTC

Regeneron Pharmaceuticals traded roughly flat in after-market hours, reflecting a slight decline since Thursday's close and remaining near the lower end of its one-month range.

2026. g. 17. jūn. 19:53 UTC

Macro Event

Regeneron Pharmaceuticals is declining in Wednesday's session, despite positive U.S. retail sales data. Shares remain below their 20-day moving average.

2026. g. 16. jūn. 19:16 UTC

Regeneron Pharmaceuticals Inc shares are lower today, with no specific news identified. Broader market sentiment may be affected by recent economic data.

2026. g. 15. jūn. 13:36 UTC

Regeneron Pharmaceuticals Inc shares are lower in pre-market hours. The stock is near the lower end of its one-month range, indicating routine price action.

2026. g. 13. jūn. 00:01 UTC

Regeneron Pharmaceuticals shares are modestly higher in after-market trading, though no specific news was identified to explain the movement.

2026. g. 12. jūn. 19:16 UTC

Shares of Regeneron Pharmaceuticals are modestly higher today, gaining traction after a flat start. The stock remains below its 20-day moving average.

Salīdzinājums

Cenas izmaiņa

Regeneron Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

24.22% augšup

Prognoze 12 mēnešiem

Vidējais 814.9 USD  24.22%

Augstākais 1,000 USD

Zemākais 641 USD

Pamatojoties uz 21 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Regeneron Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

21 ratings

15

Pirkt

6

Turēt

0

Pārdot

Noskaņojums

By Acuity

274 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
help-icon Live chat